IN THE CLAIMS

11. (AMENDED) A method of performing a phototherapeutic procedure which comprises:

(a) administering an effective amount of an organic azide photosensitizer having the formula

$$E—L—Ar—X—N_3$$

administer to whom?

wherein Ar is an aromatic or a heteroaromatic radical derived [illegible] of benzenes, polyfluorobenzenes, naphthalenes, naphthoquinones, anthracenes, anthraquinones, phenanthrenes, tetracenes, naphthacenediones, pyridines, quinolines, isoquinolines, indoles, isoindoles, pyrroles, imidiazoles, pyrazoles, pyrazines, purines, benzimidazoles, benzofurans, dibenzofurans, carbazoles, acridines, acridones, phenanthridines, thiophenes, benzothiophenes, dibenzothiophenes, xanthenes, xanthones, flavones, coumarins, and anthacylines; E is a hydrogen atom or is selected from the group consisting of somatostatin receptor binding molecules, ST receptor binding molecules, neurotensin receptor binding molecules, bombesin receptor binding molecules, CCK receptor binding molecules, steroid receptor binding molecules, and carbohydrate receptor binding molecules; L is selected from the group consisting of -$(CH_2)_a$-, -$(CH_2)_b$CONR^1-, -N(R^2)CO$(CH_2)_c$-, -OCO$(CH_2)_d$-, -$(CH_2)_e$CO$_2$-, -OCONH-, -OCO_2-, -HNCONH-, -HNCSNH-, -HNNHCO-, -OSO_2-, -NR$^3(CH_2)_e$CONR^4-, -CONR$^5(CH_2)_f$NR^{6}CO-, and -NR^{7}CO$(CH_2)_g$CONR^8-; X is either a single bond or is

selected from the group consisting of $-(CH_2)_h-$, -OCO-, -HNCO-, $-(CH_2)_iCO-$, and $-(CH_2)_jOCO-$; R^1 to R^8 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, -OH, C1-C10 polyhydroxyalkyl, C1-C10 alkoxyl, C1-C10 alkoxyalkyl, $-SO_3H$, $-(CH_2)_kCO_2H$, and $-(CH_2)_lNR^9R^{10}$; R^9 and R^{10} are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, and C1-C10 polyhydroxyalkyl; and subscripts a to l independently range from 0 to 10; and

a4

(b) exposing said target tissues with the light

no anteced. basis for "said target tissues"

and 950 nm with sufficient power and fluence rate to perfor

procedure.

Add the following new claims.

21. (NEW) The method of claim 11 further comprising the step of allowing said photosensitizer to accumulate in said target tissue before exposing said tissue to light.

22. (NEW) The method of claim 11 wherein the photosensitizer is in a concentration ranging from about 1 nM to about 0.5 M.

a5

23. (NEW) The method of claim 11 wherein the photosensitizer is in a concentration ranging from 1 μM to 10 mM.

24. (NEW) The method of claim 11 wherein the photosensitizer is parenterally administered within a formulation including pharmaceutically acceptable substances

selected from the group consisting of buffers, emulsifiers, surfactants, electrolytes, and combinations thereof.

25. (NEW) The method of claim 11 wherein the photosensitizer is administered by a method selected from the group consisting of aerosol spray, cutaneously, parenterally, enterally, and topically.

26. (NEW) The method of claim 11 wherein the effective amount of the photosensitizer administered is in the range of 0.1 mg/kg body weight to 500 mg/kg body weight.

a5

27. (NEW) The method of claim 11 wherein the effective amount of the photosensitizer administered is in the range of 0.5 mg/kg body weight to 2 mg/kg body weight.

Attached hereto is a marked-up version of the changes made by this Amendment. The attached page is captioned "Version with Markings to Show Changes Made."

REMARKS

Prior to examination, the specification has been amended to correct grammatical errors. Claims have been added to more completely define the invention. The amendments are fully supported in the Application as originally filed and contain no new matter.